Add BrightSurf on Google Email

Accelerating CAR T cell therapy: Lipid nanoparticles speed up manufacturing

Researchers developed a method using lipid nanoparticles to activate T cells and deliver genetic instructions in one step, simplifying the CAR T cell manufacturing process. This new approach reduces production time from 48 hours to 24 hours and increases accessibility to patients worldwide.

SourceUniversity of Pennsylvania School of Engineering and Applied Science·JournalAdvanced Materials·TypeExperimental study·DateMar 27, 2024

An immunotherapy to overcome resistant leukemia

Researchers have discovered a new immunotherapy approach to overcome resistant leukemia by targeting the mutated TP53 gene. Combining pharmacological therapies with genetically engineered CAR T-cells increases effectiveness against cancer cells, offering promising strategies for patients with resistant disease.

SourceUniversity of Zurich·JournalEMBO Molecular Medicine·TypeExperimental study·DateMar 21, 2024

Iron restriction keeps blood stem cells young

A study published in Cell Stem Cell found that restricting iron levels in blood stem cells can reverse their decline and improve regenerative capacity. The researchers discovered that excess intracellular iron activates inflammation within HSCs, while restricted iron levels enable them to multiply and respond effectively.

SourceAlbert Einstein College of Medicine·JournalCell Stem Cell·TypeExperimental study·DateMar 8, 2024

European treatment recommendations in the fight against acute lymphoblastic leukemia

The European LeukemiaNet has published two-part guidelines for adult acute lymphoblastic leukemia treatment, covering diagnostics, prognostic factors, response assessments, and comprehensive management. These recommendations are based on a decade of systematic work by European experts, improving the prognosis of adult patients with ALL.

SourceGoethe University Frankfurt·JournalBlood·TypeMeta-analysis·DateMar 1, 2024

A Mount Sinai-led study shows early success of a novel drug in treating a rare and chronic blood cancer

A phase 2 study by Mount Sinai-led researchers demonstrates rusfertide's ability to limit excess red blood cell production in patients with polycythemia vera, a rare and chronic blood cancer. The results suggest it could replace therapeutic phlebotomy, providing improved treatment options for patients.

SourceThe Mount Sinai Hospital / Mount Sinai School of Medicine·JournalNew England Journal of Medicine·DateFeb 21, 2024

Discovered how to predict whether patients with leukemia will be sensitive to epigenetic drugs

Researchers discovered a link between single cancer cell mutations and clinical response to epigenetic therapy in myelodysplastic syndrome. Patients showing treatment benefits had decreased mutation counts in stem cells and immature granulocytes, suggesting early tumor elimination is key to therapy success.

SourceJosep Carreras Leukaemia Research Institute·JournalCancer Research Communications·TypeExperimental study·DateFeb 5, 2024

John Theurer Cancer Center (JTCC) physician co-authors clinical research on innovative oral leukemia therapy

Researchers at the John Theurer Cancer Center have co-authored a study on oral decitabine-cedazuridine therapy, which is now shown to be pharmacologically and pharmacodynamically equivalent to its intravenous counterpart. This innovation has significant potential for patient benefit and improved comfort in cancer treatment.

SourceHackensack Meridian Health·JournalThe Lancet·TypeRandomized controlled/clinical trial·DateJan 31, 2024

RNA sequencing analysis may hold the key to more accurate diagnosis and targeted treatment of pediatric B-acute lymphoblastic leukemia

A pilot study proposes a promising global genomic assay for diagnosing molecular subtypes in pediatric B-ALL, leading to more accurate diagnosis and targeted treatment options. RNA sequencing analysis accurately identified subtypes in all known cases and determined genetic subtype in 79% of previously unknown cases.

SourceElsevier·JournalJournal of Molecular Diagnostics·TypeExperimental study·DateJan 29, 2024

Immune system plays crucial step in creating blood stem cells

A microbial sensor, Nod1, plays a crucial role in the development of blood stem cells. The discovery could lead to the creation of patient-derived blood stem cells, eliminating the need for bone marrow transplants and improving lives of leukemia, lymphoma, and anemia patients. Researchers are continuing to study the complex interaction...

SourceIowa State University·JournalNature Communications·TypeExperimental study·DateDec 19, 2023

'Exceptional' results in phase III leukaemia trial

A phase III trial has found that personalised treatment for chronic lymphocytic leukaemia (CLL) can improve survival and remission rates. The trial showed that individualising therapy based on regular blood tests significantly improved progression-free and overall survival in patients with previously untreated CLL.

SourceUniversity of Leeds·JournalNew England Journal of Medicine·DateDec 10, 2023

First-in-human clinical trial of CAR T cell therapy with new binding mechanism shows promising early responses

A Phase I clinical trial of AT101, a new CAR T cell therapy targeting CD19 through a distinct binding mechanism, has shown a 100% complete response rate in patients with relapsed or refractory B cell non-Hodgkin's lymphoma. The treatment was found to be safe with manageable side effects and is expected to build upon the effectiveness o...

Leukemia cells activate cellular recycling program

A recent study by Goethe University Frankfurt has identified a mechanism that could be a suitable starting point for developing novel drugs against leukemia cells. The researchers discovered that the mutated NPM1 gene variant drives pro-autophagic activity, enabling cancer cells to recycle their structures and meet their needs.

SourceGoethe University Frankfurt·JournalCell Reports·TypeExperimental study·DateDec 4, 2023

Multinational study confirms association between CT scans in young people and increased risk of cancer

A multinational study of almost one million individuals found a strong association between exposure to radiation from CT scans in young people and an increased risk of blood cancers. The study confirms that the benefits of computed tomography outweigh the risks, but emphasizes the need for strict radiological protection measures, parti...

SourceBarcelona Institute for Global Health (ISGlobal)·JournalNature Medicine·TypeData/statistical analysis·DateNov 9, 2023

Reassessing COVID-19 precautions in 2023

The article discusses the need to reassess COVID-19 precautions in 2023, particularly for patients with hematologic malignancies. The researchers highlight the increased risk of poor response to vaccination and worse outcomes from COVID-19 infection among these patients.

SourceImpact Journals LLC·JournalOncotarget·TypeCommentary/editorial·DateSep 27, 2023

Expanding the impact of CAR T cell therapy: An immunotherapy strategy against all blood cancers

Researchers developed a new strategy to target CD45, a surface marker found on nearly all blood cells, using CRISPR base-editing. This approach aims to overcome challenges in CAR T cell therapy, which currently targets specific cancer types, and could expand treatment options for virtually all blood cancers.

SourceUniversity of Pennsylvania School of Medicine·JournalScience Translational Medicine·DateAug 31, 2023

RESEARCH ALERT: City of Hope scientists unravel how TET2 gene deficiency fuels development of acute myeloid leukemia

Researchers identified how low TET2 levels fuel rapid growth of acute myeloid leukemia in animal models. The study found that TET2 deficiency sets off biochemical changes enhancing the cancer's ability to spread. This discovery highlights potential therapeutic targets for treating aggressive bone marrow cancer.

SourceCity of Hope·JournalCell Stem Cell·TypeExperimental study·DateAug 17, 2023